Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2014011091
pages 133-141

NK Cells in Therapy of Cancer

Veronika Bachanova
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN
Jeffrey S. Miller
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN

ABSTRAKT

Natural killer (NK) cells recognize targets stressed by malignant transformation or infection and can be long-lived. They become educated by interacting with major histocompatibility antigen (MHC) class I molecules to gain function to kill targets and produce cytokines. In the clinic, haploidentical NK cells can be adoptively transferred to treat cancer. Persistence and in vivo expansion of NK cells depends on lymphodepleting chemotherapy to make space and induce release of endogenous IL-15. In vivo expansion is also enhanced by cytokine administration but IL-2 has the down side of stimulating CD25hi regulatory T cells (Tregs). Other limitations to NK-cell therapy include poor in vivo survival and lack of specificity. Bispecific or trispecific killer engagers that target CD16 on NK cells to enhance recognition of tumor antigens, and desintegrin and metalloproteinase 17 (ADAM17) inhibition that prevents CD16 shedding after NK-cell activation should promote enhanced killing of cancer with specificity. These are exciting times; more than 35 years after NK cells were initially described, we are exploiting their capacity for clinical therapy.


Articles with similar content:

CD4+ T Cells in Adoptive Immunotherapy and the Indirect Mechanism of Tumor Rejection
Critical Reviews™ in Immunology, Vol.20, 2000, issue 1
Liaomin Peng, David E. Weng, Peter A. Cohen, Suyu Shu, Julian A. Kim, Gregory E. Plautz
Regulation of the Adhesion versus Cytotoxic Functions of the Mac-1/CR3/αMβ2 - lntegrin Glycoprotein
Critical Reviews™ in Immunology, Vol.20, 2000, issue 3
Gordon D. Ross
Immunological Protection Against Mycobacterium tuberculosis Infection
Critical Reviews™ in Immunology, Vol.26, 2006, issue 6
Yasunobu Yoshikai
T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Brian J. Czerniecki, Jorgen Kjaergaard, Liaomin Peng, Peter A. Cohen, Gary K. Koski, James H. Finke, Suyu Shu, Gregory E. Plautz
Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer
Critical Reviews™ in Immunology, Vol.40, 2020, issue 2
Tamara Lah Turnsek, Barbara Breznik, Meng-Wei Ko, Kristin Y. Nguyen, Janko Kos, Kawaljit Kaur, Anahid Jewett, Paul Wong, Emanuela Senjor